Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking approach to diabetes management. These innovative therapies operate by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to food. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin secretion and suppress gluc

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing contrasts in their